Raymond James cuts Alnylam stock rating on Amvuttra uncertainty
Raymond James downgraded Alnylam Pharmaceuticals (ALNY) to Outperform from Strong Buy, lowering its price target to $315 from $420. The move follows Alnylam's Q3 2026 results, citing uncertainty around Amvuttra's near-term trends. The stock has dropped 22% in a week, trading near its 52-week low. Despite beating earnings estimates, concerns about softer guidance and commercial delays led to the downgrade. Stifel also downgraded ALNY to Hold, reducing its price target to $225.
How this was made
The 30-second read
Why it matters
The downgrade reflects heightened uncertainty around Amvuttra, which could delay commercial momentum and pressure the stock further.
Market read
Analyst downgrade with a new price target provides a clear, time‑sensitive trading signal for ALNY.
What to watch
Stifel also cut its target, indicating consensus on near‑term concerns; however, the earnings beat and large market opportunity ($20B TAM) may support a longer‑term upside.
Background
Alnylam posted Q3 2026 earnings that beat forecasts due to a one‑time tax benefit, but guidance for its TTR franchise was softened, prompting analyst downgrades.
Ticker impact
Raymond James downgraded Alnylam Pharmaceuticals to Outperform and cut the price target to $315, citing uncertainty around the Amvuttra TTR franchise.
downward pressure as the market prices in the reduced target and visibility concerns
The downgrade is a fresh analyst action with a concrete price‑target change; traders can act on the new guidance today.
Market effects
The downgrade may weigh on other RNA‑interference and rare‑disease biotech stocks as investors reassess TTR franchise risk.
Primarily U.S. biotech sector; limited broader market effect.
Low; impact confined to ALNY and close peers.
Counterpoint
If Amvuttra rebounds or the one‑time tax benefit recurs, the stock could be oversold after the downgrade.
Key entities
- companyAlnylam Pharmaceuticals
US‑listed biotech (NASDAQ:ALNY) developing RNAi therapeutics.
- analyst_firmRaymond James
Equity research firm issuing the downgrade.
